Latest On Takeda Pharmaceutical Company Limited (TAK):
About Takeda Pharmaceutical Company Limited (TAK):
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; and strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
General
- Name Takeda Pharmaceutical Company Limited
- Symbol TAK
- Type Common Stock
- Exchange NYSE
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 47,495
- Fiscal Year EndMarch
- IPO Date2008-10-27
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Web URLhttp://www.takeda.com
Valuation
- Trailing PE 23.78
- Forward PE 10.55
- Price/Sales (Trailing 12 Mt.) 2.1
- Price/Book (Most Recent Quarter) 1.45
- Enterprise Value Revenue 0.03
- Enterprise Value EBITDA 0.11
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.85
- Next Year EPS Estimate $0.97
- Profit Margin 6%
- Return on Assets 1%
- Return on Equity 4%
- Earnings Per Share $0.81
- Revenue Per Share $0
- Gross Profit 2.2 trillion
- Quarterly Earnings Growth -2.6%
Highlights
- Market Capitalization 61.57 billion
- PE Ratio 51.15
- PEG Ratio 0.14
- Analyst Target Price $22.79
- Book Value Per Share $12.55
Share Statistics
- Shares Outstanding 3.15 billion
- Shares Float 3.13 billion
- % Held by Insiders <1%
- % Held by Institutions 3.5%
- Shares Short 6.57 million
- Shares Short Prior Month 6.19 million
- Short Ratio 1.52
Technicals
- Beta 1.11
- 52 Week High $19.67
- 52 Week Low $13.11
- 50 Day Moving Average 17.7
- 200 Day Moving Average 17.77
Dividends
- Forward Annual Dividend Rate $0.85
- Forward Annual Dividend Yield 4.4%
- Payout Ratio 39%
- Dividend Date 2009-12-15
- ExDividend Date 2020-09-29
- Dividend Per Share $1.64
- Dividend Yield 4.06%
Takeda Pharmaceutical Company Limited (TAK) Dividend Calendar:
Takeda Pharmaceutical Company Limited pays an annual dividend of $0.85 per share, with a dividend yield of 4.06%.
TAK's last dividend payment was made to shareholders on December 15, 2009.
Takeda Pharmaceutical Company Limited pays out 39% of its earnings out as a dividend.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Takeda Pharmaceutical Company Limited (TAK) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2021-02-05 | $836.75 billion | $0.28 | ||
2020-09-30 | 2020-11-02 | $N/A | $1.10 | $103.00 | -98.93% |
2020-06-30 | 2020-07-31 | $N/A | $0.25 | $0.79 | -68.66% |
2020-03-31 | 2020-05-13 | $771.7 billion | $0.55 | ||
2019-12-31 | 2020-02-04 | $7.91 billion | $3.00 | $75.00 | -96% |
2019-09-30 | 2019-11-13 | $7.5 billion | $0.16 | ||
2019-06-30 | 2019-07-31 | $7.84 billion | -$0.06 | ||
2019-03-31 | 2019-05-14 | $6.44 billion | -$0.16 | ||
2018-12-31 | 2019-02-01 | $4.56 billion | $0.21 | ||
2018-09-30 | 2018-10-31 | $3.78 billion | $0.28 | ||
2018-06-30 | 2018-07-31 | $4.06 billion | $0.46 | ||
2018-03-31 | 2018-05-14 | $3.79 billion | -$0.32 | ||
2017-12-31 | 2018-02-01 | $4.33 billion | $0.38 | ||
2017-09-30 | 2017-11-01 | $0.16 | |||
2017-06-30 | 2017-07-28 | $0.83 | |||
2017-03-31 | 2017-05-10 | -$0.29 | |||
2016-12-31 | 2017-02-01 | $0.24 | |||
2016-09-30 | 2016-10-28 | $0.15 | |||
2016-06-30 | 2016-07-29 | $0.59 | |||
2016-03-31 | 2016-05-10 | -$0.19 | |||
2015-12-31 | 2016-02-03 | $0.31 | |||
2015-09-30 | 2015-10-30 | $0.15 | |||
2015-06-30 | 2015-07-30 | $0.13 | |||
2015-03-31 | 2015-05-15 | -$1.20 | |||
2014-12-31 | 2015-02-05 | $0.10 | |||
2014-09-30 | 2014-10-30 | $0.17 | |||
2014-06-30 | 2014-08-01 | $0.21 | |||
2014-03-31 | 2014-05-08 | -$0.13 | |||
2013-12-31 | 2014-02-05 | $0.29 | |||
2013-09-30 | 2013-10-31 | $0.23 | |||
2013-06-30 | 2013-07-31 | $0.19 | |||
2013-03-31 | 2013-05-09 | -$0.05 | |||
2012-12-31 | 2013-02-04 | $0.15 | |||
2012-09-30 | 2012-10-31 | $0.26 | |||
2012-06-30 | 2012-07-30 | $0.69 | |||
2012-03-31 | 2012-05-11 | -$0.29 | |||
2011-12-31 | 2012-02-01 | $0.20 | |||
2011-09-30 | 2011-11-04 | $0.49 | |||
2011-06-30 | 2011-07-29 | $0.59 | |||
2011-03-31 | 2011-05-11 | $0.25 | |||
2010-12-31 | 2011-02-03 | $0.55 | |||
2010-09-30 | 2010-10-29 | $0.60 | |||
2010-06-30 | 2010-07-30 | $0.45 | |||
2008-09-30 | 2008-11-04 | $0.39 | |||
2008-06-30 | 2008-07-31 | $0.01 | |||
2008-03-31 | 2008-05-09 | $0.14 |
Takeda Pharmaceutical Company Limited (TAK) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Takeda Pharmaceutical Company Limited (TAK) Chart:
Takeda Pharmaceutical Company Limited (TAK) News:
Below you will find a list of latest news for Takeda Pharmaceutical Company Limited (TAK) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Takeda Pharmaceutical Company Limited (TAK) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|---|---|---|---|---|---|---|---|---|
2025-04-17 | 2.5 | 0 | CALL | 0 | 0 | 578.78 | TRUE | 0 | 0 |
2025-04-17 | 5 | 0 | CALL | 0 | 0 | 405.93 | TRUE | 0 | 0 |
2025-04-17 | 7.5 | 0 | CALL | 0 | 0 | 534.92 | TRUE | 0 | 0 |
2025-04-17 | 10 | 3.74 | CALL | 0 | 1 | 110.33 | TRUE | 0 | 0 |
2025-04-17 | 12.5 | 2.57 | CALL | 0 | 17 | 82.1 | TRUE | 0 | 0 |
2025-04-17 | 15 | 0.15 | CALL | 1 | 705 | 9.72 | TRUE | 0.15 | 0 |
2025-04-17 | 17.5 | 0.1 | CALL | 0 | 367 | 38.77 | FALSE | 0 | 0 |
2025-04-17 | 20 | 0.75 | CALL | 0 | 200 | 88.72 | FALSE | 0 | 0 |
2025-04-17 | 22.5 | 0.04 | CALL | 0 | 14 | 85.38 | FALSE | 0 | 0 |
2025-04-17 | 25 | 0.05 | CALL | 0 | 9 | 129.91 | FALSE | 0 | 0 |
2025-04-17 | 2.5 | 0 | PUT | 0 | 0 | 629.92 | FALSE | 0 | 0 |
2025-04-17 | 5 | 0 | PUT | 0 | 0 | 390.23 | FALSE | 0 | 0 |
2025-04-17 | 7.5 | 0 | PUT | 0 | 0 | 262.64 | FALSE | 0 | 0 |
2025-04-17 | 10 | 0 | PUT | 0 | 0 | 173.25 | FALSE | 0 | 0 |
2025-04-17 | 12.5 | 0.05 | PUT | 0 | 105 | 64.31 | FALSE | 0 | 0 |
2025-04-17 | 15 | 0.3 | PUT | 0 | 204 | 24.93 | FALSE | 0 | 0 |
2025-04-17 | 17.5 | 2.7 | PUT | 0 | 2 | 102.54 | TRUE | 0 | 0 |
2025-04-17 | 20 | 0 | PUT | 0 | 0 | 143.25 | TRUE | 0 | 0 |
2025-04-17 | 22.5 | 0 | PUT | 0 | 0 | 170.27 | TRUE | 0 | 0 |
2025-04-17 | 25 | 0 | PUT | 0 | 0 | 196.83 | TRUE | 0 | 0 |
2025-05-16 | 2.5 | 0 | CALL | 0 | 0 | 377.16 | TRUE | 0 | 0 |
2025-05-16 | 5 | 0 | CALL | 0 | 0 | 222.32 | TRUE | 0 | 0 |
2025-05-16 | 7.5 | 0 | CALL | 0 | 0 | 194.2 | TRUE | 0 | 0 |
2025-05-16 | 10 | 0 | CALL | 0 | 0 | 111.67 | TRUE | 0 | 0 |
2025-05-16 | 12.5 | 0 | CALL | 0 | 0 | 61.18 | TRUE | 0 | 0 |
2025-05-16 | 15 | 0.37 | CALL | 0 | 212 | 25.28 | TRUE | 0 | 0 |
2025-05-16 | 17.5 | 0 | CALL | 0 | 0 | 33.92 | FALSE | 0 | 0 |
2025-05-16 | 20 | 0 | CALL | 0 | 0 | 40.75 | FALSE | 0 | 0 |
2025-05-16 | 22.5 | 0 | CALL | 0 | 0 | 95.58 | FALSE | 0 | 0 |
2025-05-16 | 25 | 0 | CALL | 0 | 0 | 137.5 | FALSE | 0 | 0 |
2025-05-16 | 30 | 0 | CALL | 0 | 0 | 146.97 | FALSE | 0 | 0 |
2025-05-16 | 2.5 | 0 | PUT | 0 | 0 | 396.46 | FALSE | 0 | 0 |
2025-05-16 | 5 | 0 | PUT | 0 | 0 | 272.18 | FALSE | 0 | 0 |
2025-05-16 | 7.5 | 0 | PUT | 0 | 0 | 183.97 | FALSE | 0 | 0 |
2025-05-16 | 10 | 0 | PUT | 0 | 0 | 108.81 | FALSE | 0 | 0 |
2025-05-16 | 12.5 | 0 | PUT | 0 | 0 | 87.26 | FALSE | 0 | 0 |
2025-05-16 | 15 | 0.52 | PUT | 0 | 6 | 29 | FALSE | 0 | 0 |
2025-05-16 | 17.5 | 0 | PUT | 0 | 0 | 63.96 | TRUE | 0 | 0 |
2025-05-16 | 20 | 0 | PUT | 0 | 0 | 56.57 | TRUE | 0 | 0 |
2025-05-16 | 22.5 | 0 | PUT | 0 | 0 | 92.8 | TRUE | 0 | 0 |
2025-05-16 | 25 | 0 | PUT | 0 | 0 | 94.78 | TRUE | 0 | 0 |
2025-05-16 | 30 | 0 | PUT | 0 | 0 | 130.87 | TRUE | 0 | 0 |
2025-07-18 | 2.5 | 0 | CALL | 0 | 0 | 284.91 | TRUE | 0 | 0 |
2025-07-18 | 5 | 8.74 | CALL | 0 | 2 | 264.89 | TRUE | 0 | 0 |
2025-07-18 | 7.5 | 0 | CALL | 0 | 0 | 129.21 | TRUE | 0 | 0 |
2025-07-18 | 10 | 3.55 | CALL | 0 | 7 | 63.02 | TRUE | 0 | 0 |
2025-07-18 | 12.5 | 2.66 | CALL | 0 | 92 | 37.56 | TRUE | 0 | 0 |
2025-07-18 | 15 | 0.62 | CALL | 0 | 404 | 19.08 | TRUE | 0 | 0 |
2025-07-18 | 17.5 | 0.1 | CALL | 2 | 103 | 22.78 | FALSE | 0.1 | 0 |
2025-07-18 | 20 | 0 | CALL | 0 | 0 | 40.73 | FALSE | 0 | 0 |
2025-07-18 | 22.5 | 0 | CALL | 0 | 0 | 76.89 | FALSE | 0 | 0 |
2025-07-18 | 25 | 0 | CALL | 0 | 0 | 73.72 | FALSE | 0 | 0 |
2025-07-18 | 2.5 | 0 | PUT | 0 | 0 | 286.17 | FALSE | 0 | 0 |
2025-07-18 | 5 | 0 | PUT | 0 | 0 | 161.38 | FALSE | 0 | 0 |
2025-07-18 | 7.5 | 0 | PUT | 0 | 0 | 118.86 | FALSE | 0 | 0 |
2025-07-18 | 10 | 0 | PUT | 0 | 0 | 90.18 | FALSE | 0 | 0 |
2025-07-18 | 12.5 | 0.08 | PUT | 0 | 138 | 26.04 | FALSE | 0 | 0 |
2025-07-18 | 15 | 0.65 | PUT | 4 | 32 | 19.01 | FALSE | 0.65 | 0 |
2025-07-18 | 17.5 | 2.8 | PUT | 0 | 1 | 42.1 | TRUE | 0 | 0 |
2025-07-18 | 20 | 0 | PUT | 0 | 0 | 58.61 | TRUE | 0 | 0 |
2025-07-18 | 22.5 | 0 | PUT | 0 | 0 | 60.75 | TRUE | 0 | 0 |
2025-07-18 | 25 | 0 | PUT | 0 | 0 | 53.77 | TRUE | 0 | 0 |
2025-10-17 | 2.5 | 0 | CALL | 0 | 0 | 565.3 | TRUE | 0 | 0 |
2025-10-17 | 5 | 0 | CALL | 0 | 0 | 261.3 | TRUE | 0 | 0 |
2025-10-17 | 7.5 | 0 | CALL | 0 | 0 | 92.07 | TRUE | 0 | 0 |
2025-10-17 | 10 | 0 | CALL | 0 | 0 | 60.58 | TRUE | 0 | 0 |
2025-10-17 | 12.5 | 2.48 | CALL | 0 | 6 | 24.69 | TRUE | 0 | 0 |
2025-10-17 | 15 | 0.86 | CALL | 0 | 230 | 16.27 | TRUE | 0 | 0 |
2025-10-17 | 17.5 | 0.17 | CALL | 0 | 154 | 19.58 | FALSE | 0 | 0 |
2025-10-17 | 20 | 0 | CALL | 0 | 0 | 26.81 | FALSE | 0 | 0 |
2025-10-17 | 22.5 | 0 | CALL | 0 | 0 | 57.79 | FALSE | 0 | 0 |
2025-10-17 | 25 | 0 | CALL | 0 | 0 | 60.07 | FALSE | 0 | 0 |
2025-10-17 | 2.5 | 0 | PUT | 0 | 0 | 282.05 | FALSE | 0 | 0 |
2025-10-17 | 5 | 0 | PUT | 0 | 0 | 130.57 | FALSE | 0 | 0 |
2025-10-17 | 7.5 | 0 | PUT | 0 | 0 | 87.91 | FALSE | 0 | 0 |
2025-10-17 | 10 | 0 | PUT | 0 | 0 | 58.2 | FALSE | 0 | 0 |
2025-10-17 | 12.5 | 0.2 | PUT | 0 | 6 | 43.27 | FALSE | 0 | 0 |
2025-10-17 | 15 | 0.98 | PUT | 0 | 1 | 26.47 | FALSE | 0 | 0 |
2025-10-17 | 17.5 | 0 | PUT | 0 | 0 | 29.43 | TRUE | 0 | 0 |
2025-10-17 | 20 | 0 | PUT | 0 | 0 | 16.65 | TRUE | 0 | 0 |
2025-10-17 | 22.5 | 0 | PUT | 0 | 0 | 22.63 | TRUE | 0 | 0 |
2025-10-17 | 25 | 0 | PUT | 0 | 0 | 39.42 | TRUE | 0 | 0 |
Latest TAK Trades:
Date | Shares | Price |
---|---|---|
Jun 13, 2022 7:58 PM EST | 100 | $13.18 |
Jun 13, 2022 7:59 PM EST | 5 | $13.185 |
Jun 13, 2022 7:59 PM EST | 100 | $13.185 |
Jun 13, 2022 7:59 PM EST | 395 | $13.185 |
Jun 13, 2022 7:59 PM EST | 5 | $13.175 |
Takeda Pharmaceutical Company Limited (TAK) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000122/0001395064-20-000122-index.htm |
2019-08-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1395064/000000000019012497/0000000000-19-012497-index.htm |
2020-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000083423720006759/0000834237-20-006759-index.htm |
2020-07-09 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1395064/000087666120000553/0000876661-20-000553-index.htm |
2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000094562120000061/0000945621-20-000061-index.htm |
2019-11-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000110465919060139/0001104659-19-060139-index.htm |
2019-11-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000117911019011437/0001179110-19-011437-index.htm |
2019-05-20 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000119312519151456/0001193125-19-151456-index.htm |
2019-05-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312519160545/0001193125-19-160545-index.htm |
2019-05-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312519161779/0001193125-19-161779-index.htm |
2019-06-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312519172962/0001193125-19-172962-index.htm |
2019-06-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312519172969/0001193125-19-172969-index.htm |
2019-06-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312519174175/0001193125-19-174175-index.htm |
2019-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312519175179/0001193125-19-175179-index.htm |
2020-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520177563/0001193125-20-177563-index.htm |
2020-06-24 | F-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1395064/000119312520177693/0001193125-20-177693-index.htm |
2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520178182/0001193125-20-178182-index.htm |
2020-06-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520178198/0001193125-20-178198-index.htm |
2020-06-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520178205/0001193125-20-178205-index.htm |
2020-06-30 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1395064/000119312520183171/0001193125-20-183171-index.htm |
2020-06-30 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1395064/000119312520183261/0001193125-20-183261-index.htm |
2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520183271/0001193125-20-183271-index.htm |
2020-06-30 | 424B2 | Prospectus [Rule 424(b)(2)] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520183299/0001193125-20-183299-index.htm |
2020-06-30 | 424B2 | Prospectus [Rule 424(b)(2)] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520183322/0001193125-20-183322-index.htm |
2020-07-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520190209/0001193125-20-190209-index.htm |
2020-07-09 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1395064/000119312520190236/0001193125-20-190236-index.htm |
2019-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000120919119042489/0001209191-19-042489-index.htm |
2019-10-24 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000120919119054013/0001209191-19-054013-index.htm |
2019-06-27 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/0001395064-19-000005-index.htm |
2019-06-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000006/0001395064-19-000006-index.htm |
2019-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000008/0001395064-19-000008-index.htm |
2019-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000011/0001395064-19-000011-index.htm |
2019-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000013/0001395064-19-000013-index.htm |
2019-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000015/0001395064-19-000015-index.htm |
2019-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000017/0001395064-19-000017-index.htm |
2019-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000019/0001395064-19-000019-index.htm |
2019-08-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000022/0001395064-19-000022-index.htm |
2019-08-09 | F-4 | Registration of securities, foreign private issuers, business combinations | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000024/0001395064-19-000024-index.htm |
2019-09-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000027/0001395064-19-000027-index.htm |
2019-09-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000029/0001395064-19-000029-index.htm |
2019-10-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000035/0001395064-19-000035-index.htm |
2019-10-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000037/0001395064-19-000037-index.htm |
2019-11-06 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000040/0001395064-19-000040-index.htm |
2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000042/0001395064-19-000042-index.htm |
2019-11-12 | F-4/A | Registration of securities, foreign private issuers, business combinations | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000050/0001395064-19-000050-index.htm |
2019-11-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000052/0001395064-19-000052-index.htm |
2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000058/0001395064-19-000058-index.htm |
2019-11-14 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000060/0001395064-19-000060-index.htm |
2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000062/0001395064-19-000062-index.htm |
2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000064/0001395064-19-000064-index.htm |
2019-11-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000067/0001395064-19-000067-index.htm |
2019-11-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000072/0001395064-19-000072-index.htm |
2019-11-22 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000080/0001395064-19-000080-index.htm |
2019-11-22 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000081/0001395064-19-000081-index.htm |
2019-11-22 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000082/0001395064-19-000082-index.htm |
2019-11-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000083/0001395064-19-000083-index.htm |
2019-11-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000085/0001395064-19-000085-index.htm |
2019-12-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000088/0001395064-19-000088-index.htm |
2020-01-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000003/0001395064-20-000003-index.htm |
2020-01-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000007/0001395064-20-000007-index.htm |
2020-01-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000010/0001395064-20-000010-index.htm |
2020-01-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000020/0001395064-20-000020-index.htm |
2020-01-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000021/0001395064-20-000021-index.htm |
2020-01-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000024/0001395064-20-000024-index.htm |
2020-02-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000029/0001395064-20-000029-index.htm |
2020-02-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000030/0001395064-20-000030-index.htm |
2020-02-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000033/0001395064-20-000033-index.htm |
2020-02-26 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000037/0001395064-20-000037-index.htm |
2020-03-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000040/0001395064-20-000040-index.htm |
2020-04-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000043/0001395064-20-000043-index.htm |
2020-04-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000045/0001395064-20-000045-index.htm |
2020-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000052/0001395064-20-000052-index.htm |
2020-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000054/0001395064-20-000054-index.htm |
2020-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000056/0001395064-20-000056-index.htm |
2020-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000058/0001395064-20-000058-index.htm |
2020-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000060/0001395064-20-000060-index.htm |
2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000068/0001395064-20-000068-index.htm |
2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000070/0001395064-20-000070-index.htm |
2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000073/0001395064-20-000073-index.htm |
2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000075/0001395064-20-000075-index.htm |
2020-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000078/0001395064-20-000078-index.htm |
2020-06-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000081/0001395064-20-000081-index.htm |
2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm |
2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000084/0001395064-20-000084-index.htm |
2020-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000087/0001395064-20-000087-index.htm |
2020-06-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000090/0001395064-20-000090-index.htm |
2020-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000105/0001395064-20-000105-index.htm |
2020-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000106/0001395064-20-000106-index.htm |
2020-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000107/0001395064-20-000107-index.htm |
2020-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000108/0001395064-20-000108-index.htm |
2020-06-24 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/0001395064-20-000110-index.htm |
2020-06-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000113/0001395064-20-000113-index.htm |
2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000115/0001395064-20-000115-index.htm |
2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000118/0001395064-20-000118-index.htm |
2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000120/0001395064-20-000120-index.htm |
2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000122/0001395064-20-000122-index.htm |
2020-07-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000124/0001395064-20-000124-index.htm |
2020-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000132/0001395064-20-000132-index.htm |
2020-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000133/0001395064-20-000133-index.htm |
2020-08-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000138/0001395064-20-000138-index.htm |
2020-08-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000141/0001395064-20-000141-index.htm |
2020-08-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000144/0001395064-20-000144-index.htm |
2020-08-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000147/0001395064-20-000147-index.htm |
2020-09-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000150/0001395064-20-000150-index.htm |
2020-10-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000153/0001395064-20-000153-index.htm |
2020-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000158/0001395064-20-000158-index.htm |
2020-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000160/0001395064-20-000160-index.htm |
2020-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000162/0001395064-20-000162-index.htm |
2019-11-14 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1395064/999999999519002568/9999999995-19-002568-index.htm |
2020-03-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1395064/999999999520000449/9999999995-20-000449-index.htm |
Takeda Pharmaceutical Company Limited (TAK) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Takeda Pharmaceutical Company Limited (TAK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: < 1%Institutional Ownership: 350%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2020-06-30 | Shire Human Genetic Therapies, Inc. | 10% Share Holder | Sell | 6,824,992.00 | 20.68 | 141,140,834.56 | 0.00 | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000122/0001395064-20-000122-index.htm |
2019-10-08 | PHARMACEUTICAL CO LTD TAKEDA | 10% Share Holder | Buy | 2,000,000.00 | 2.50 | 5,000,000.00 | 5,750,000.00 | https://www.sec.gov/Archives/edgar/data/1395064/000139506419000083/0001395064-19-000083-index.htm |
2020-06-03 | Shire Human Genetic Therapies, Inc. | 10% Share Holder | Sell | 40,086.00 | 19.75 | 791,698.50 | 6,824,992.00 | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000084/0001395064-20-000084-index.htm |
2020-06-02 | Shire Human Genetic Therapies, Inc. | 10% Share Holder | Sell | 5,006.00 | 20.02 | 100,220.12 | 6,865,078.00 | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm |
2020-06-02 | Shire Human Genetic Therapies, Inc. | 10% Share Holder | Sell | 100,389.00 | 19.75 | 1,982,682.75 | 6,870,084.00 | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm |
2020-06-01 | Shire Human Genetic Therapies, Inc. | 10% Share Holder | Sell | 1,400.00 | 20.53 | 28,742.00 | 6,970,473.00 | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm |
2020-06-01 | Shire Human Genetic Therapies, Inc. | 10% Share Holder | Sell | 107,072.00 | 19.85 | 2,125,379.20 | 6,971,873.00 | https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm |